BACKGROUND AND OBJECTIVES: The available data on the immunoglobulin gene (IG) repertoire in multiple myeloma (MM) derive mainly from heavy chains; considerably less is known about light chains. We assessed in parallel IGH and IGK/IGL rearrangements in 101 MM patients so as to gain insight into: (i) IG repertoires; (ii) antigen impact; (iii) the role of receptor editing. DESIGN AND METHODS: Bone marrow aspirates were collected from all cases. IGHV-(D)-J and IGLV-J rearrangements were amplified by reverse transcriptase polymerase chain reaction (PCR). In all cases, IGKV-J rearrangements were analyzed in parallel on cDNA/genomic DNA. IGKV-KDE and IGKJ-C-INTRON-KDE were also amplified by DNA-PCR. RT-PCR products were directly sequenced. RESULTS: IGHV3 genes predominated; the IGHV4-34 gene was used in only one case. Five IGKV and five IGLV genes accounted for the majority of in-frame, transcribed IGKV-J or IGLV-J rearrangements. Taking IGKV-J, IGKV-KDE and IGKJ-C-INTRON-KDE rearrangements together, biallelic IGK locus rearrangements were detected in 22/43 k-MM cases. In l-MM, 36/42 cases had at least one rearranged IGK allele; 8/19 IGKV-J rearrangements in l-MM were in-frame. All in-frame, transcribed IGH/IGK/IGL sequences were mutated; parallel heavy/light chain analysis demonstrated a comparable impact of somatic hypermutation. INTERPRETATION AND CONCLUSIONS: Biases in IG repertoire did not seem disease-related but followed a similar pattern to that of the normal repertoire. The under-representation of the IGHV4-34 gene provides an explanation for the paucity of autoimmune phenomena in MM. Somatic mutation patterns indicate the complementary role of MM IGH/IGK/IGL sequences in antigen recognition. Finally, the frequent inactivation of productive IGKV-J joints by secondary rearrangements in MM suggests active receptor editing.
BACKGROUND AND OBJECTIVES: The available data on the immunoglobulin gene (IG) repertoire in multiple myeloma (MM) derive mainly from heavy chains; considerably less is known about light chains. We assessed in parallel IGH and IGK/IGL rearrangements in 101 MM patients so as to gain insight into: (i) IG repertoires; (ii) antigen impact; (iii) the role of receptor editing. DESIGN AND METHODS: Bone marrow aspirates were collected from all cases. IGHV-(D)-J and IGLV-J rearrangements were amplified by reverse transcriptase polymerase chain reaction (PCR). In all cases, IGKV-J rearrangements were analyzed in parallel on cDNA/genomic DNA. IGKV-KDE and IGKJ-C-INTRON-KDE were also amplified by DNA-PCR. RT-PCR products were directly sequenced. RESULTS: IGHV3 genes predominated; the IGHV4-34 gene was used in only one case. Five IGKV and five IGLV genes accounted for the majority of in-frame, transcribed IGKV-J or IGLV-J rearrangements. Taking IGKV-J, IGKV-KDE and IGKJ-C-INTRON-KDE rearrangements together, biallelic IGK locus rearrangements were detected in 22/43 k-MM cases. In l-MM, 36/42 cases had at least one rearranged IGK allele; 8/19 IGKV-J rearrangements in l-MM were in-frame. All in-frame, transcribed IGH/IGK/IGL sequences were mutated; parallel heavy/light chain analysis demonstrated a comparable impact of somatic hypermutation. INTERPRETATION AND CONCLUSIONS: Biases in IG repertoire did not seem disease-related but followed a similar pattern to that of the normal repertoire. The under-representation of the IGHV4-34 gene provides an explanation for the paucity of autoimmune phenomena in MM. Somatic mutation patterns indicate the complementary role of MM IGH/IGK/IGL sequences in antigen recognition. Finally, the frequent inactivation of productive IGKV-J joints by secondary rearrangements in MM suggests active receptor editing.
Authors: H Robert Bergen; Surendra Dasari; Angela Dispenzieri; John R Mills; Marina Ramirez-Alvarado; Renee C Tschumper; Diane F Jelinek; David R Barnidge; David L Murray Journal: Clin Chem Date: 2015-10-01 Impact factor: 8.327
Authors: M Ladetto; M Brüggemann; L Monitillo; S Ferrero; F Pepin; D Drandi; D Barbero; A Palumbo; R Passera; M Boccadoro; M Ritgen; N Gökbuget; J Zheng; V Carlton; H Trautmann; M Faham; C Pott Journal: Leukemia Date: 2013-12-17 Impact factor: 11.528
Authors: Ramy Arnaout; William Lee; Patrick Cahill; Tracey Honan; Todd Sparrow; Michael Weiand; Chad Nusbaum; Klaus Rajewsky; Sergei B Koralov Journal: PLoS One Date: 2011-08-04 Impact factor: 3.240
Authors: Renee C Tschumper; Yan W Asmann; Asif Hossain; Paul M Huddleston; Xiaosheng Wu; Angela Dispenzieri; Bruce W Eckloff; Diane F Jelinek Journal: Oncotarget Date: 2012-04
Authors: Alejandro Medina; Cristina Jiménez; M Eugenia Sarasquete; Marcos González; M Carmen Chillón; Ana Balanzategui; Isabel Prieto-Conde; María García-Álvarez; Noemí Puig; Verónica González-Calle; Miguel Alcoceba; Isabel Cuenca; Santiago Barrio; Fernando Escalante; Norma C Gutiérrez; Mercedes Gironella; Miguel T Hernández; Anna Sureda; Albert Oriol; Joan Bladé; Juan-José Lahuerta; Jesús F San Miguel; María-Victoria Mateos; Joaquín Martínez-López; María-José Calasanz; Ramón García-Sanz Journal: Blood Cancer J Date: 2020-02-06 Impact factor: 11.037